States and traits related to the quality and consequences of psychedelic experiences.
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Many individuals experience significant positive psychological change after ingesting psychedelic agents such as psilocybin, LSD, and ayahuasca, but some do not. Such changes appear to be mediated by definable and measurable mystical experiences (MEs) during the psychedelic session, which have been shown in previous research (e.g., Griffiths, Richards, McCann, & Jesse, 2006) to be related to long-term positive personal change. Individual responses to psychedelic agents are characteristically difficult to predict, however, necessitating improved identification of predictors to (a) reduce the possibility of significant challenging experiences and sequelae and (b) increase the possibility of MEs and long-term beneficial outcomes. Our study utilized crowdsourced retrospective survey data from 143 Amazon Mechanical Turk participants who self-administered psilocybin in the past year to identify factors related to MEs and/or challenging experiences. The best performing regression model explained 66% of the variance in ME scores on the 30-item Mystical Experience Questionnaire (MacLean, Leoutsakos, Johnson, & Griffiths, 2012) and 56% of the variance in scores on the dread subscale of the Sacred Emotions Scale (Burdzy, 2014). A state of surrender at the start of the psilocybin session most strongly explained MEs, and a state of preoccupation most strongly explained challenging experiences. The trait absorption was a strong secondary predictor in both models, along with smaller predictors. Additionally, the occurrence of MEs during the psilocybin session explained long-term positive change. Based on these findings, the presented models appear to provide a powerful framework for explaining the immediate quality and long-term consequences of psychedelic experiences. Limitations as well as implications for therapeutic applications are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366 · cited 3×
“Some researchers have argued that MEs cannot be measured on a continuous linear scale but instead involve an inflection or transition point into “complete” MEs that appears to be strongly dose-dependent (Barrett et al., 2015; Griffiths et al., 2011). Validated criteria and thresholds for determining the occurrence of…”
BackgroundInfluential
Cited by
Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375
Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00014 · Cited by 224
Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169
“Several measures have been developed for assessment of acute subjective psychedelic drug effects that occur in the laboratory and in naturalistic settings (Davis et al., 2018, 2020; Griffiths et al., 2006, 2011; Kometer et al., 2015; Roseman et al., 2018; Russ et al., 2019).”
BackgroundWolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
“Relatedly, previous studies have provided evidence that verbal interactions during psilocybin sessions may hinder the emergence of mystical-type experiences (Russ et al., 2019a,b).”
Background
Metadata
- Authors
- Russ, S. L., Carhart-Harris, R. L., Maruyama, G., & Elliott, M. S.
- Venue
- Psychology of Consciousness: Theory, Research, and Practice
- Published
- 2019-03
- Volume
- 6
- Issue
- 1
- Pages
- 1-21
- ISSN
- 2326-5523 (ISSN-L)
- 2326-5531
- OpenAlex
- W2903884088
- Cited by
- 55
- References
- 1
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.